Last updated on July 2017

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B


Brief description of study

This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir.

Detailed Study Description

This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir. HBeAg-negative subjects will be randomized to receive low or high dose vaccine, in the presence or absence of IC31® adjuvant, or to receive placebo or IC31® adjuvant alone.

Clinical Study Identifier: NCT02496897

Contact Investigators or Research Sites near you

Start Over

Byoung Kuk Jang, MD

Keimyung University Dongsan Medical Center
Daegu, Korea, Republic of
  Connect »

Won Young Tak, MD

Kyungpook National University Hospital
Daegu, Korea, Republic of
0.97miles
  Connect »